AURORA, ON, Aug. 17, 2017 /CNW/ - Prollenium Medical Technologies Inc., a leading medical device manufacturer, announced today its United States (U.S.) Food and Drug Administration (FDA) approval for its cross-linked hyaluronic acid dermal filler. Ario Khoshbin, Founder and CEO, stated "This is definitely one of our proudest moments as an organization. FDA approval is a culmination of efforts from every single member of our team. As an organization, we have been working towards this goal from the first day the company opened its doors, and to see it come to fruition is a validation of our vision. The U.S. market and its potential will be an exciting challenge for our team, but one that will have many rewards for our business both in the U.S. and globally."
Founded in 2002, Prollenium Medical Technologies Inc. has developed a pipeline of innovative products for tissue reconstruction by focusing its attention on the R&D, marketing, and sales of novel biomaterials that can be used in a wide array of tissue reconstruction applications.1 Prollenium manufactures its products in-house at its Aurora manufacturing plant.
SOURCE Prollenium Medical Technologies Inc.
For further information: Media: Bryan Appel, Manager, Corporate Communications, [email protected]